- Cytek Biosciences (CTKB, Financial) launches the Cytek Aurora™ Evo, an enhanced full spectrum flow cytometer.
- The Aurora Evo introduces 2x faster sample acquisition and integrated small particle detection.
- Improved instrument standardization and automation features aim to enhance laboratory efficiency.
In a significant advancement in flow cytometry technology, Cytek Biosciences, Inc. (CTKB) has unveiled the Cytek Aurora™ Evo, an upgraded version of its flagship full spectrum flow cytometer. This new model enhances the capabilities of the original Aurora system, which has been widely recognized, appearing in over 2,600 peer-reviewed publications.
The Cytek Aurora Evo introduces key improvements, including a doubled sample acquisition speed and automated maintenance, which reduces technical overhead and standardizes results. Another pivotal enhancement is the built-in small particle detection capability, previously available only as an optional upgrade. This feature allows researchers to effectively analyze small particles such as extracellular vesicles, viruses, and nanoparticles, broadening the scope of research applications.
With throughput capabilities reaching up to 200 µL/min, the Aurora Evo ensures high-efficiency sample processing. The system's integrated automation, featuring an automated plate loader, further streamlines laboratory workflows, enabling higher throughput with reduced downtime.
Cytek's Full Spectrum Profiling™ (FSP®) technology remains at the core of the Aurora Evo, supporting large multicolor experiments by providing exceptional sensitivity and resolution. These advancements solidify Cytek's leadership in the field of cell analysis, particularly benefitting research in immunology, oncology, and therapeutic development.
The Cytek Aurora Evo will make its public debut at CYTO 2025, demonstrating Cytek's commitment to expanding the frontiers of cell analysis technology with innovative, user-friendly solutions.
